Press release
Companion Diagnostics Market to Reach USD 5.0 Billion by 2024 and at estimated CAGR of 12.0% to 2024
SEATTLE, WA, 2018-Mar-27 — /openPR/ —Simultaneous development of a companion diagnostic test and the drug candidate has its own set of pros and cons that act as a trade-off for pharmaceutical companies. Developing companion diagnostic risks holding up of effective drug therapies, and making major investments on companion diagnostics early is a perceived risk, as many drug candidates fail to make it to the market. However, personalized medicine is the emerging therapeutic approach for cancer and other chronic therapies. Thus, developing a companion diagnostic for faster FDA approval makes it imperative for researchers to invest in the development of CDx tests.
To understand Research Methodology, please click: https://www.coherentmarketinsights.com/insight/request-sample/109
Agilent technologies, Inc. announced the extended use of its CE approved Dako PD-L1 IHC 22C3 pharmDx in January 2017, in determining PD-L1 expression status in patients with metastatic non-small cell lung cancer (NSCLC). This device helps determine the expression level of PD-L1 in both untreated and previously treated metastatic NSCLC patients with KEYTRUDA (pembrolizumab), a first-line treatment drug for metastatic NSCLC. With this approval, patients with metastatic NSCLC and in the second-line or later treatment settings can also be identified for treatment with KEYTRUDA.
Invivoscribe Technologies Inc., has companion diagnostics development deal with Novartis AG and Astellas Pharma Inc. Invivoscribe Technologies Inc. has developed a companion diagnostic test for FLT3, a biomarker for the stratification and prognosis of acute myeloid leukemia (AML). This CDx is under the U.S. FDA review for its use with PKC412 (midostaurin) an investigational drug for adults with newly-diagnosed AML and who are FLT3 mutation-positive. If granted approval the LeukoStrat CDx FLT3 Mutation Assay would be the first CDx for AML.
Approval of the drug and CDx test at the same time is difficult. However, the endeavor to develop effective targeted therapies at low cost and faster time to market would encourage more drug developers to conduct clinical trials with diagnostics as part of the inclusion/exclusion criteria.
Potential lowering of cost and clinical benefits driving the companion diagnostics market
Growth of companion diagnostics market relies on the ecosystem of pharmaceuticals industry. A more collaborative approach would benefit payors and providers of healthcare products and services. CDx supports drug developers in reducing development costs, develop highly effective therapeutic product, and improve the time to market by identifying the effectiveness of a drug against particular biomarkers. The payors (patients) benefit from better treatment outcomes and lower morbidity risk. Moreover, with the advent of advanced technologies such as PCR, immunohistochemistry and gene sequencing, accurate diagnosis, and determination of targeted cancer therapy is much easier.
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/109
Advancements in technology and increasing research on CDx has resulted in increasing approval of drug therapies with diagnostic tests alongside it. As per the Regulatory Affirms Professionals Society (RAPS), the share of drugs and biologics approved alongside a diagnostic test, by the U.S. FDA, increased from 20% in 2014 to 28% in 2015.
Increasing number of research collaborations is expected to improve the time to market of highly effective targeted drug therapies. This would in-turn augment the growth of companion diagnostics market.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Companion Diagnostics Market to Reach USD 5.0 Billion by 2024 and at estimated CAGR of 12.0% to 2024 here
News-ID: 994055 • Views: …
More Releases from Clinical Diagnostic Market Report

Women’s Health Diagnostic Test Market - By Application Ovarian Cancer Test, Br …
In 2017, Naugatuck Valley Women’s Health Specialists (NVWHS) decided to provide a free informational program for heart health with Boston Heart Diagnostics. Boston Heart diagnostics has anticipating treatment and diagnosis of cardiovascular diseases (CVD), which improves women’s heart health, as CVD is a leading disease in the U.S. This program is expected to create awareness of CVD related diseases among women and also help to improve lifestyle.
Download The PDF Brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/971…

Non-Invasive Cancer Diagnostics Market- Trends And Outlook
Non-invasive cancer diagnostics are procedures used for the identification of cancer without incision in the body. Detection and treatment of cancer at early stages are important for long-term survival. Non-invasive cancer detection method is found to be an increasing choice of interest, owing to its painless or minimal pain method of diagnostic coupled with more accurate results. Molecular based diagnostic methods are expected to increase during the forecast period due…

Molecular Diagnostics Market - Global Industry Insights
Molecular diagnostics tests are used for detecting disturbance between specific sequences in DNA or RNA, which may be associated with disease. The disturbance between a single nucleotide polymorphism (SNP), deletions, rearrangements, insertions, and others factors lead to various diseases. Disease that are diagnosed by using molecular diagnostic test includes infectious diseases, oncology, virology, and STDs.
Increasing incidence and prevalence of infectious disease and cancer is expected to be a major factor…

Autoimmune Disease Diagnostics Market - Global Industry Insights, Trends, 2017†…
The immune system of human body recognize some invaders such as bacteria, viruses, and external chemicals and attacks those to protect the body. However, sometimes the immune system attacks the healthy cells of body by considering them as foreign cells. Such a condition is called autoimmune disease. The autoimmune disease causes abnormal organ growth and changes in organ function. The genes of an individual with environmental exposure might be the…
More Releases for CDx
Global Pharmacogenomics Technology Theranostics CDx Outlook Market Analysis (202 …
LPI (LP Information)' newest research report, the "Pharmacogenomics Technology Theranostics CDx Outlook Industry Forecast" looks at past sales and reviews total world Pharmacogenomics Technology Theranostics CDx Outlook sales in 2025, providing a comprehensive analysis by region and market sector of projected Pharmacogenomics Technology Theranostics CDx Outlook sales for 2025 through 2031. With Pharmacogenomics Technology Theranostics CDx Outlook sales broken down by region, market sector and sub-sector, this report provides a…
Pharmacogenomics Technology (Theranostics & CDx) market size ascends with a CAGR …
The global Pharmacogenomics Technology (Theranostics & CDx) market size was valued at USD 9869.6 million in 2022 and is forecast to a readjusted size of USD 24800 million by 2029 with a CAGR of 14.1% during review period. The global Pharmacogenomics Technology market has witnessed remarkable growth in recent years, driven by advancements in genetic research, personalized medicine, and the increasing demand for targeted therapies. Pharmacogenomics, the study of how…
Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) Market Over …
The Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) market report is a perfect foundation for people looking out for a comprehensive study and analysis of the Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) market. On the basis of historic growth analysis and current scenario of Pharmacogenomics Technology-Theranostics-Companion Diagnostics (CDx) market place, the report intends to offer actionable insights and outlook on global / regional market growth projections. Authenticated data presented in report is based on findings…
Pharmacogenomics Technology Or Theranostics Or Companion Diagnostics (CDx) Marke …
The market study contains demand, application information, price trends, historical and projected market data, company shares of the top Pharmacogenomics Technology Or Theranostics Or Companion Diagnostics (CDx) providers by region. According on application type, geography, and market size (by volume and value), the report segments the market. This report's main goal is to aid the reader in understanding the market in terms of its definition, segmentation, market potential, significant trends,…
Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market …
The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a robust research methodology model that helps to make informed decisions. It obtains both qualitative and quantitative market information supported by primary research.
The Pharmacogenomics Technology…
Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market …
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market survey report has been prepared by conducting market research in a…